相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction
Luna Prieto Garcia et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach
Sumit Bhatnagar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles
Andrzej Czyrski et al.
PHARMACEUTICS (2021)
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial
Nora Isberner et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma
Fatemeh Aghai et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2021)
A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP
Marival Bermejo et al.
PHARMACEUTICS (2020)
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Madan Jagasia et al.
BLOOD (2020)
Pharmacokinetics and Pharmacodynamics of Posaconazole
Lu Chen et al.
DRUGS (2020)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects
Vassilios Aslanis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability
Haiyan Li et al.
CLINICAL DRUG INVESTIGATION (2019)
Population Pharmacokinetics of Ruxolitinib in Patients with aGVHD Who Had an Inadequate Response to Corticosteroids
Xuejun Chen et al.
BLOOD (2019)
Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the US Food and Drug Administration's Office of Clinical Pharmacology
Manuela Grimstein et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Application of a Dynamic Fluid and pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus™
Bart Hens et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model
Bart Hens et al.
AAPS JOURNAL (2018)
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Sibylle C. Mellinghoff et al.
ANNALS OF HEMATOLOGY (2018)
Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development
Yumi Cleary et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Physiologically Based Pharmacokinetic Modeling in Regulatory Decision-Making at the European Medicines Agency
E. Luzon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole
Rodrigo Cristofoletti et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole
Bart Hens et al.
MOLECULAR PHARMACEUTICS (2017)
Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
A. S. Darwich et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease (vol 71, pg 718, 2016)
Oliver A. Cornely et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Differences in Food Effects for 2 Weak Bases With Similar BCS Drug-Related Properties: What Is Happening in the Intestinal Lumen?
Rodrigo Cristofoletti et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models
Simone Hansmann et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2016)
Effect of a High-Fat Meal on the Pharmacokinetics of 300-Milligram Posaconazole in a Solid Oral Tablet Formulation
Wendy M. Kersemaekers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
State-of-the-art acute and chronic GVHD treatment
Muhammad Omer Jamil et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Pharmacokinetics and Safety Study of Posaconazole Intravenous Solution Administered Peripherally to Healthy Subjects
Wendy M. Kersemaekers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration
Christian Wagner et al.
CLINICAL PHARMACOKINETICS (2015)
Predicting Drug-Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib
J. G. Shi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Renal and Hepatic Impairment Patients
Xuejun Chen et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2014)
A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers
Yoichiro Ogama et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension
Gopal Krishna et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
Paul J. Martin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers
G. Krishna et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms
Kirstin Thelen et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole Monitoring of Intraluminal and Plasma Drug Concentrations
Jeroen Walravens et al.
CLINICAL PHARMACOKINETICS (2011)
The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
Jack G. Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Evolution of a Detailed Physiological Model to Simulate the Gastrointestinal Transit and Absorption Process in Humans, Part 1: Oral Solutions
Kirstin Thelen et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview
Hans-Peter Lipp
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Population-Based Mechanistic Prediction of Oral Drug Absorption
Masoud Jamei et al.
AAPS JOURNAL (2009)
Simultaneous Determination of Voriconazole and Posaconazole Concentrations in Human Plasma by High-Performance Liquid Chromatography
Kathrin Kahle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Effects of Oral Posaconazole on the Pharmacokinetic Properties of Oral and Intravenous Midazolam: A Phase I, Randomized, Open-Label, Crossover Study in Healthy Volunteers
Gopal Krishna et al.
CLINICAL THERAPEUTICS (2009)
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
Andrew J. Ullmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients
Zahida Bhatti et al.
MYCOPATHOLOGIA (2006)
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients
Paul O. Gubbins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Development and evaluation of a generic physiologically based pharmacokinetic model for children
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2006)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Oral bioavailability of posaconazole in fasted healthy subjects - Comparison between three regimens and basis for clinical dosage recommendations
F Ezzet et al.
CLINICAL PHARMACOKINETICS (2005)
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study
D Wexler et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)
A Ghosal et al.
DRUG METABOLISM AND DISPOSITION (2004)
分享论文
